The convergence of pharmacology and artificial intelligence (AI) represents a frontier in both the development of new therapeutic agents and the personalized treatment of diseases. Pharmacology, the study of drugs and their effects on living organisms, has traditionally been a domain of extensive research and development. Artificial intelligence, with its capabilities in analyzing vast datasets, predicting outcomes, and optimizing processes, offers revolutionary potential when applied to pharmacology. This fusion, which we might term Pharmako-AI, could signify a paradigm shift in drug discovery, development, and therapeutic application.
The author (unknown, but sharp) suggests three “dosing protocols”: pharmako-ai pdf
The third aspect of the pharmakon—the scapegoat—is highly relevant to the current discourse on AI. In the Pharmakos role, the AI is anthropomorphized
In the Pharmakos role, the AI is anthropomorphized and cast out (regulated, banned, or "aligned") in an attempt to purify society. Yet, because the AI is a mirror of the data we feed it (our collective unconscious), casting it out is an attempt to cast out the darker parts of ourselves. In the Pharmakos role